拜卡莱因通过依赖FXR的方式调节胆汁酸代谢来缓解肝脏内胆固醇酶
相关实验视频
Updated: Jul 1, 2025

06:55
Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
9.5K
Weifan Huang1, Yihan Qian1, Jiacheng Lin1
1Central Laboratory, ShuGuang Hospital Affiliated to Shanghai University of Chinese Traditional Medicine, Shanghai, China.
Biochemical and biophysical research communications
|March 5, 2024
概括
拜卡莱因通过减少炎症和纤维化,在治疗胆固醇性肝病方面表现有前途. 它的治疗效果依赖于Farnesoid X受体 (FXR),这表明一种有针对性的治疗方法.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 胆固醇性肝病涉及胆汁流失,导致肝损伤和纤维化.
- 目前的治疗方法,如UDCA和OCA有局限性和副作用.
- 开发有效的胆固醇治疗药理疗法仍然是一个重大的临床挑战.
研究的目的:
- 在胆固醇性肝损伤的小鼠模型中研究贝卡莱因的治疗潜力.
- 阐明贝卡莱因作用背后的机制,特别是其与Farnesoid X受体 (FXR) 的相互作用.
主要方法:
- 通过使用3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) 饮食诱导胆固醇的小鼠模型.
- 在小鼠的治疗中,使用或不使用腹腔内注射贝卡莱因.
- 通过与Guggulsterone (GS),一种FXR抗剂同时使用Baicalein来评估FXR的作用.
主要成果:
- 拜卡莱因治疗显著减轻了饮食引起的DDC肝炎,状反应和纤维化.
- 拜卡莱因在胆固醇模型中改善了胆酸代谢障碍.
- 当Guggulsterone阻断FXR时,贝卡莱因的保护作用会减弱.
结论:
- 拜卡莱因在小鼠中对DDC饮食诱导的胆固醇性肝损伤表现出显著的治疗疗效.
- 拜卡莱因的有益作用通过一种依赖于FXR的途径进行介导.
- 拜卡莱因代表了胆固醇性肝病的潜在新型治疗剂.
更多相关视频
相关概念视频
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Hepatic Drug Excretion: Influencing Factors
129
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
129
Drugs for Treatment of Constipation-Predominant IBS
163
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
163
Chronic Bowel Disorders: Introduction
450
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
450
Drugs for Treatment of Diarrhea-Predominant IBS
169
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
169
Hepatic Drug Clearance: Role of Transporters
56
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
56

